Focus Stocks
Is GlaxoSmithKline Closing in to Resistance?
Published on Thursday, 07 February 2013 07:12 Written by TradersHuddle Wire
New York, February 7th (TradersHuddle.com) - Shares of GlaxoSmithKline plc (NYSE:GSK) are trading very close to calculated resistance at $47.40. The stock ended the trading session at just $45.42, which is near levels that make it difficult to buy or start a position.
GlaxoSmithKline plc (NYSE:GSK) is a research-based pharmaceutical group that develops, manufactures and markets vaccines, prescription and over-the-counter medicines, as well as health-related consumer products. Its over the counter medicines and health related consumer products are marketed under brand names like Panadol, Nicorette, Breathe Right, Tums, Aquafresh, and Sensodyne among others.
GlaxoSmithKline's stock range is defined by its calculated support defined at $41.68 and by the resistance level at $47.40; the stock is clearly over-extended from support, making it harder for participants to establish fresh longs.
Traders don't have a clear entry point for GlaxoSmithKline. However, as the stock pulls back towards $41.68 it will definitely provide a reference point to establish a trade. On the other hand, if the stock breaks above its resistance level at $47.40 then traders will get an opportunity to enter the stock as it moves to a higher range.
Related Articles
- GlaxoSmithKline Is Near its 50 Day Moving Average
- Critical Alerts For Anheuser-Busch InBev, GlaxoSmithKline, Capital One, Safeway, and Onyx Pharmaceuticals Released By InvestorsObserver
- GlaxoSmithKline near Support
- Approaching Support: GlaxoSmithKline
- GlaxoSmithKline Is Near a Key Resistance Area
- Close to the 50 Day Moving Average: GlaxoSmithKline
- GlaxoSmithKline Is Close to the 50 Day Moving Average
- Two new GSK oral oncology treatments, BRAF-inhibitor Tafinlar® (dabrafenib) capsules and the first MEK-inhibitor Mekinist™ (trametinib) tablets, approved by FDA as single-agent therapies
- GlaxoSmithKline Is Near Resistance
- GlaxoSmithKline Is Near a Key Resistance Area
Related Partner Headlines
- GlaxoSmithKline Stock To Go Ex-dividend Tomorrow (GSK) - TheStreet.com
- GlaxoSmithKline PLC (GSK): Today's Featured Drugs Laggard - TheStreet.com
- Buzz on Sarepta's Eteplirsen From London Duchenne Meeting - TheStreet.com
- GlaxoSmithKline PLC (GSK): Today's Featured Health Care Winner - TheStreet.com
- GlaxoSmithKline PLC (GSK): Today's Featured Health Care Winner - TheStreet.com
- United Therapeutics Could Lose The Battle For PAH Therapies - TheStreet.com
- A Prescription for Election Fever - TheStreet.com
- GlaxoSmithKline PLC (GSK): Today's Featured Drugs Laggard - TheStreet.com
- How to Hedge Profits in Sarepta Therapeutics - TheStreet.com
- Lazard Analyst Note on Sarepta Therapeutics Is Generating Buzz - TheStreet.com
TradersHuddle Search
|
Stock Search: |
|
Site Search: Loading
|
Recent Trading Ideas
Latest Partner Headlines
-
Dow Today: Verizon Communications (VZ) Higher - TheStreet.com -
Separating the Bargains From the Busts - TheStreet.com -
Cramer Quick Take: The 60-Inch TV Will Be Key This Holiday - TheStreet.com -
Cramer Quick Take: Cisco Wins If Fiscal Cliff Is Resolved - TheStreet.com -
Gap Up and Sit - TheStreet.com -
Apple, Intel, MicroStrategy: Tech Winners & Losers - TheStreet.com -
Windows 8 PC Sales Disappointing: Report - TheStreet.com -
Cramer Quick Take: Buy Home Depot and Lowe's - TheStreet.com
Stock Market
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:15,318.23 Trade time:4:34PM EDT Value change:0.00 (0.00%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,651.81 Trade time:4:34PM EDT Value change:0.00 (0.00%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:3,482.18 Trade time:5:15PM EDT Value change:0.00 (0.00%)In The Wires
-
AVT's Customer, Marley Coffee Automated Stores, On Track to Take Significant Market Share in Automated Coffee Space -
TSX Delisting Review - Noveko International Inc. (Symbol: EKO) -
Air Lease Corporation Selects Pratt & Whitney PurePower® Engines for Airbus A320/A321 neo Aircraft -
CryoLife Receives Conditional IDE Approval to Begin Clinical Trials for PerClot® in the U.S. -
Gladstone Commercial Corporation Announces Pricing of Common Stock Offering -
Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence -
Commerce Resources Corp. Announces 2013 Summer Drill Program at the Ashram Rare Earth Element Deposit, Northern Quebec -
FMC Corporation Announces Dates for Second Quarter 2013 Earnings Release and Webcast Conference Call








